Presentation is loading. Please wait.

Presentation is loading. Please wait.

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma  Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Similar presentations


Presentation on theme: "Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma  Viktor Grünwald, Xun Lin, Daniel Kalanovic,"— Presentation transcript:

1 Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma  Viktor Grünwald, Xun Lin, Daniel Kalanovic, Ronit Simantov  European Urology  Volume 70, Issue 6, Pages (December 2016) DOI: /j.eururo Copyright © Terms and Conditions

2 Fig. 1 Receiver operating characteristic analysis of overall survival and progression-free survival. Vascular endothelial growth factor–targeted agents include axitinib, bevacizumab plus temsirolimus, sorafenib, and sunitinib. Treatment with temsirolimus includes both single-agent temsirolimus and temsirolimus plus interferon α. D=point with shortest distance to the optimal point; IFN=interferon; OS=overall survival; PFS=progression-free survival; VEGF=vascular endothelial growth factor. European Urology  , DOI: ( /j.eururo ) Copyright © Terms and Conditions

3 Fig. 2 Kaplan-Meier estimates. (a) Overall survival and (b) progression-free survival in patients with and without early tumour shrinkage; (c) OS and (d) PFS in patients with or without objective response by Response Evaluation Criteria in Solid Tumours. CI=confidence interval; eTS=early tumour shrinkage; HR=hazard ratio; OS=overall survival; PFS=progression-free survival; RECIST=Response Evaluation Criteria in Solid Tumours. European Urology  , DOI: ( /j.eururo ) Copyright © Terms and Conditions

4 Fig. 3 Cox proportional hazards analysis of (a) overall survival and (b) progression-free survival. Early tumour shrinkage ≥10% (yes) versus <10% (no). Vascular endothelial growth factor–targeted agents include axitinib, bevacizumab plus temsirolimus, sorafenib, and sunitinib. Treatment with temsirolimus includes both single-agent temsirolimus and temsirolimus plus interferon-α. CI=confidence interval; ECOG PS=Eastern Cooperative Oncology Group performance status; eTS=early tumour shrinkage; HR=hazard ratio; IFN=interferon; LLN=lower limit of normal; ULN=upper limit of normal; VEGF=vascular endothelial growth factor. European Urology  , DOI: ( /j.eururo ) Copyright © Terms and Conditions


Download ppt "Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma  Viktor Grünwald, Xun Lin, Daniel Kalanovic,"

Similar presentations


Ads by Google